BioCentury
ARTICLE | Finance

Ante up on Omontys

Affymax shares surge on rumors of an Omontys comeback

March 11, 2013 7:00 AM UTC

There was no shortage of rumors seeking to explain last week's spike in shares of Affymax Inc. (NASDAQ:AFFY), but the big unanswered question remains whether anemia drug Omontys peginesatide has a path back to market after last month's recall.

Affymax jumped $1.23 (54%) to $3.52 on Thursday, clawing back some of what the biotech lost after it and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) pulled the drug on Feb. 23 because of reports of serious hypersensitivity reactions - including three deaths due to serious anaphylactic reactions (see BioCentury, March 4). ...